Vysis' PathVysion Likely Challenger As Dako's HercepTest Enters Market
This article was originally published in The Gray Sheet
Executive Summary
If Vysis' presentation to FDA's Nov. 9 Immunology Devices Panel serves as any indication, the company's pending commercial introduction of the PathVysion HER-2 DNA Probe Kit will be aimed specifically at taking market share from Dako's HercepTest (see related story, p. 13).
You may also be interested in...
Abbott/Vysis’ PathVysion HER-2 Assay Endorsed By Herceptin Panel Review
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.